Soolantra (Ivermectin) 1% Cream: A Novel, Antibiotic-Free Agent Approved for the Treatment of Patients with Rosacea
Rosacea is a chronic and progressive skin condition characterized by episodes of remission and exacerbations of its many cutaneous symptoms, including flushing, facial erythema, telangiectasia, edema, papules, pustules, ocular lesions, and rhinophyma. Approximately 16 million individuals in the United States are affected by rosacea. The incidence of rosacea is increasing with aging. Rosacea is more frequently observed in women than in men; however, men with rosacea often have more disfiguring skin changes than women.
Tanzeum (Albiglutide): A Once-Weekly GLP-1 Receptor Agonist Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes
Diabetes affects 25.8 million individuals in the United States, an estimated 8.3% of the US population. Furthermore, approximately 79 million US adults aged >20 years have prediabetes. Based on the aging of the US population and its projected increasing incidence in the coming decades, diabetes is estimated to affect 1 in 3 US adults by 2050. Effective preventive strategies, particularly in high-risk individuals, may reduce the projected increase in the prevalence of diabetes.
Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes
Diabetes, a chronic disease that is often accompanied by multiple comorbidities and health complications, is the seventh leading medical cause of death in the United States. In fact, the mortality rate for patients with diabetes is 1.5 times higher than for individuals without diabetes. Diabetes affects an estimated 29.1 million individuals in the United States—an alarming 9.3% of the US population. In addition, an estimated 37% of US adults aged ≥20 years have prediabetes, according to the 2009-2012 National Health and Nutrition Examination Survey data. The prevalence of diabetes is projected to increase from 1 in 10 adults today to 1 in 3 adults by 2050, coinciding with the aging of the baby boom generation during the next few decades. Type 2 diabetes mellitus accounts for approximately 90% to 95% of all cases of diabetes.
Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma
Multiple myeloma, also referred to as myeloma, is a malignant neoplasm of plasma cells in the bone marrow that leads to bone destruction and bone marrow failure. According to the American Cancer Society, an estimated 26,850 new cases of myeloma will be diagnosed in 2015, and 11,240 deaths will be attributed to myeloma.
Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection
Approximately 130 million to 170 million individuals worldwide, including 3.2 million Americans, are infected with chronic hepatitis C virus (HCV), making it the most common blood-borne disease. Chronic HCV infection is a silent epidemic; the disease can remain quiescent for decades before clinically significant symptoms appear.
Zontivity (Vorapaxar), First-in-Class PAR-1 Antagonist, Receives FDA Approval for Risk Reduction of Heart Attack, Stroke, and Cardiovascular Death
In the United States, heart disease is the number one cause of death, claiming the lives of approximately 600,000 people annually—a staggering 1 in every 4 deaths. Coronary heart disease (CHD) alone accounts for nearly 380,000 deaths yearly. Myocardial infarction (MI) is a common type of CHD affecting 720,000 Americans every year. Of these total MIs, 515,000 are first MIs, and 205,000 are recurrent MIs.
Zydelig (Idelalisib): First-in-Class PI3 Kinase Inhibitor Approved for the Treatment of 3 Hematologic Malignancies
Chronic lymphocytic leukemia (CLL), a cancer of B-cell lymphocytes, is the most common type of leukemia in Western adult patients. According to the Leukemia and Lymphoma Society, more than 15,600 Americans were diagnosed with CLL in 2013.
Zykadia (Ceritinib) Approved for Patients with Crizotinib-Resistant ALK-Positive Non–Small-Cell Lung Cancer
Lung cancer is one of the most frequently diagnosed cancers, as well as the leading cause of cancer-related mortality in the United States. According to the American Cancer Society, more than 159,000 Americans will die from lung cancer in 2014, representing approximately 27% of all cancer deaths. Non–small-cell lung cancer (NSCLC), the most common form of lung cancer, accounts for 85% to 90% of all cases. NSCLC comprises a number of histologies, including adenocarcinoma, squamous-cell carcinoma, nonsquamous carcinoma, large-cell carcinoma, sarcomatoid carcinoma, and adenosquamous carcinoma.
Glyxambi (Empagliflozin/Linagliptin): A Dual- Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes
Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer
Thyroid cancer, cancer that starts in the thyroid gland, accounts for 3.8% of all cancer cases in the United States. There were an estimated 62,980 new cases of thyroid cancer and 1890 deaths resulting from thyroid cancer in 2014. Thyroid cancer is most common in people aged 45 to 54 years (median age, 50 years), and it occurs 2 to 3 times more often in women than in men. The incidence of thyroid cancer has risen steadily in recent years. Although this increasing rate can be attributed largely to disease detection at an earlier stage, the incidence of larger tumors has also increased.
Page 6 of 7
Results 51 - 60 of 69
Results 51 - 60 of 69